Articles tagged "Alloantibodies"

2016 American Transplant Congress
Fc Receptor Binding Assay for Functional Assessment of HLA Antibodies: Initial Clinical Validation.
E. Woodle, A. Girnita.
U of Cincinnati, Cincinnati.
Functional assessment of HLA antibodies (Abs) has historically been limited to complement-based assays, which have known limitations. Moreover, HLA Abs mediate injury by complement-independent mechanisms,…
2016 American Transplant Congress
Eculizumab for Chronic Antibody-Mediated Injury in Kidney Transplant Recipients: A Randomized-Controlled Trial.
S. Kulkarni,¹ N. Kirkiles-Smith,² Y. Deng,³ R. Formica,⁴ M. Gilbert,⁵ V. Broeckner,⁶ L. Bow,¹ J. Pober.²
¹Surgery, Yale University, New Haven, CT; ²Immunobiology, Yale University, New Haven, CT; ³Yale Center for Analytical Sciences, Yale School of Public Health, New Haven, CT; ⁴Medicine, Yale University, New Haven, CT; ⁵Pathology, Yale University, New Haven, CT; ⁶Histopathology, Univeristy of Cambridge, Cambridge, United Kingdom.
Purpose: We hypothesize that de novo donor specific antibody (DSA) in kidney transplant patients cause endothelial cell injury that is dependent on complement and treatment…
2016 American Transplant Congress
Posttransplant AT1Rabs Precede De Novo HLA-DSA Development.
J. Arreola-Guerra,³ E. Cuevas,¹ E. Hernandez-Mendez,¹ M. Vilatoba,¹ A. Contreras,¹ J. Ramirez,¹ D. de Rongs,¹ J. Granados,¹ L. Morales-Buenrostro,² J. Alberu.¹
¹Transplantation, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico; ²Nephrology and Mineral Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico; ³Tranplantation, Instituto de Servicios de Salud del Estado de Aguascalientes, Aguascalientes, Mexico.
Angiotensin II type 1 receptor antibodies (AT1Rabs) have been associated with acute allograft rejection and graft loss. The possible implication of the generation of de…
2016 American Transplant Congress
Successful Treatment of Established Acute Allograft Rejection with Delayed CTLA-4Ig.
J. Young,¹ J. Chen,¹ D. Yin,¹ R. Sciammas,² V. Vu,¹ M.-L. Alegre,³ A. Chong.¹
¹Transplant Surgery, University of Chicago, Chicago, IL; ²Medicine, Houston Methodist Research Institute, Houston, TX; ³Medicine, University of Chicago, Chicago, IL.
Purpose: Our goal was to determine the efficacy and immune mechanisms of costimulation blockade by CTLA-4Ig when treatment begins after an immune response is already…
2016 American Transplant Congress
Epitope Load Is Predictive of De Novo Donor Specific Antibodies Occurrence in Renal Transplant Recipients After Conversion from Cyclosporine to Everolimus.
R. Snanoudj,¹ C. Suberbielle,² N. Kamar,³ E. Cassuto,⁴ S. Caillard,⁵ J.-L. Taupin,² D. Anglicheau,¹ C. Legendre,¹ A. Hertig,⁶ E. Rondeau.⁶
¹Necker Hospital, Paris, France; ²Saint-Louis Hospital, Paris, France; ³Rangueil Hospital, Toulouse, France; ⁴Pasteur Hospital, Nice, France; ⁵CHRU, Strasbourg, France; ⁶Tenon Hospital, Paris, France.
IntroductionThe degree of HLA compatibility between donor and recipient is an important risk factor of developing de novo DSA, but misjudged by the number of…
2016 American Transplant Congress
Torque Teno Virus – Inverse Association with Late Silent Antibody Mediated Kidney Allograft Rejection.
G. Bond,¹ M. Schiemann,¹ F. Eskandary,¹ H. Herkner,² E. Puchhammer,³ R. Oberbauer,¹ G. Böhmig.¹
¹Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria; ²Emergency Medicine, Medical University of Vienna, Vienna, Austria; ³Virology, Medical University of Vienna, Vienna, Austria.
Clinical Problem and hypothesis: Antibody mediated rejection (ABMR) is a cardinal cause of late graft failure after kidney transplantation (KTX). A promising predictive diagnostic tool…
2016 American Transplant Congress
Type of Sensitization Does Not Impact Kidney Graft Outcome in Weakly Sensitized Patients.
A. Morrison,¹ D. Sawinski,² M. Lim,² M. Levine,¹ M. Kamoun,³ P. Porrett.¹
¹Surgery, University of Pennsylvania, Philadelphia, PA; ²Medicine, University of Pennsylvania, Philadelphia, PA; ³Pathology, University of Pennsylvania, Philadelphia, PA.
Introduction: The impact of low level sensitization on kidney transplant (KTx) outcomes is unclear. While limited data suggest that KTx outcomes are comparable between weakly…
2016 American Transplant Congress
Pre-Transplant IgM to Post-Transplant IgG DSA Conversion May Be Affected by Immunosuppression.
A. Nguyen,¹ M. Everly,¹ L. Rebellato,² C. Haisch,² K. Briley,² P. Bolin,² S. Kendrick,² C. Morgan,² A. Maldonado,² P. Terasaki.¹
¹Terasaki Foundation Laboratory, Los Angeles, CA; ²East Carolina University, Greenville, NC.
Post-transplant (tx) IgG donor-specific antibodies (DSA), but not IgM DSA has been identified as one of the major causes of late graft loss. Considering the…
2016 American Transplant Congress
HLA Antibody in Transplant Recipients During Transition from Paediatrics.
S. Kaki,¹ A. Lunn,² J. Goodwin,³ T. Key,³ W. McKane.¹
¹Renal, Sheffield Kidney Institute, Sheffield, United Kingdom; ²Renal, Queens Medical Centre, Sheffield, United Kingdom; ³Histocompatibility and Immunogenetics, National Health Service blood and transplantation, Sheffield, United Kingdom.
Objective:Adolescent transplant recipients in transition from paediatric to adult units are known to be at high risk of graft failure. Detection of HLA antibody is…
2016 American Transplant Congress
Long-Term Follow-Up of Renal Transplant Recipients (RTR) Treated with IVIG for De Novo Donor Specific Antibodies (DSA).
R. Knight,¹ S. Patel,¹ J. Loucks-DeVos,² S. Kuten,¹ A. Gaber.¹
¹Houston Methodist Hospital, Houston, TX; ²Kansas University Medical Center, Kansas City, KS.
Intravenous immune globulin (IVIG) may be beneﬁcial for pre-emptive treatment of de novo DSA in RTR without biopsy-proven acute rejection (AR). Herein, we present long-term…